secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eloxx Pharmaceuticals, Inc. (ELOX)
CIK:        0001035354
Form:       8-K
Filed at:   2021-11-09T23:59:59+00:00
Accession:  0001104659-21-136028
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eloxx reports Q3 net loss of $9.9M; Phase 2 CF data on track for Q4 2021
------------------------------------------------------------------------

- Net loss of $9.9M ($0.11/share) vs $6.6M loss; R&D spending rose to $5.2M.
- Cash $52.4M as of Sep 30, 2021; expected to fund operations into Q1 2023.
- Entered debt facility with Hercules Capital for up to $30M, initial draw $12.5M.
- Appointed Dr. Ali Hariri as Chief Medical Officer.
- FDA Fast Track designation for ELX-02; Phase 2 monotherapy data expected Q4 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1035354/000110465921136028/0001104659-21-136028-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1035354/000110465921136028/tm2132381d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-136028

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer